| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GNAI1 |
| Uniprot No | P63096 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-354aa |
| 氨基酸序列 | GCTLSAEDKAAVERSKMIDRNLREDGEKAAREVKLLLLGAGESGKSTIVKQMKIIHEAGYSEEECKQYKAVVYSNTIQSIIAIIRAMGRLKIDFGDSARADDARQLFVLAGAAEEGFMTAELAGVIKRLWKDSGVQACFNRSREYQLNDSAAYYLNDLDRIAQPNYIPTQQDVLRTRVKTTGIVETHFTFKDLHFKMFDVGGQRSERKKWIHCFEGVTAIIFCVALSDYDLVLAEDEEMNRMHESMKLFDSICNNKWFTDTSIILFLNKKDLFEEKIKKSPLTICYPEYAGSNTYEEAAAYIQCQFEDLNKRKDTKEIYTHFTCATDTKNVQFVFDAVTDVIIKNNLKDCGLF |
| 预测分子量 | 47.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GNAI1重组蛋白的3篇参考文献示例(注：文献信息为虚构，仅作格式参考)：
1. **文献名称**：*"Expression and Purification of Recombinant GNAI1 in Escherichia coli for Structural Studies"*
**作者**：Chen L, et al.
**摘要**：该研究报道了在大肠杆菌中高效表达人源GNAI1重组蛋白的优化方法，通过His标签亲和层析纯化获得高纯度蛋白，并利用X射线晶体学初步解析了其三维结构，为G蛋白信号传导机制研究提供基础。
2. **文献名称**：*"Functional Characterization of Recombinant GNAI1 in Cancer Cell Signaling Pathways"*
**作者**：Park S, et al.
**摘要**：作者通过哺乳动物细胞系统表达GNAI1重组蛋白，结合免疫共沉淀和荧光共振能量转移(FRET)技术，揭示了GNAI1与βγ亚基的相互作用动力学及其在抑制癌细胞cAMP信号通路中的关键作用。
3. **文献名称**：*"Role of Recombinant GNAI1 in Modulating Neuronal Calcium Channels"*
**作者**：Gomez-Ramos A, et al.
**摘要**：研究利用杆状病毒-昆虫细胞系统表达GNAI1重组蛋白，证明其通过结合钙通道Cav2.2亚基调控神经元钙内流，为神经退行性疾病中G蛋白偶联受体异常提供了分子机制依据。
(注：如需真实文献，建议通过PubMed或Google Scholar以关键词“GNAI1 recombinant protein”检索。)
**Background of GNAI1 Recombinant Protein**
GNAI1 (Guanine Nucleotide-Binding Protein Alpha Inhibiting Activity Polypeptide 1) is a member of the inhibitory alpha subunit family of heterotrimeric G proteins, which play critical roles in transmembrane signaling by coupling G protein-coupled receptors (GPCRs) to intracellular effector pathways. As part of the Gi/o subfamily, GNAI1 mediates the inhibition of adenylate cyclase, reducing intracellular cAMP levels, and regulates ion channels, MAPK pathways, and other downstream signaling cascades. Its activity is essential for modulating cellular responses such as proliferation, differentiation, and apoptosis.
Recombinant GNAI1 protein is engineered through molecular cloning and expression in heterologous systems (e.g., *E. coli* or mammalian cells) to produce a purified, bioactive form of the protein. This allows researchers to study its structure, function, and interactions in controlled settings. The recombinant form often includes tags (e.g., His or GST tags) for simplified purification and detection while retaining native conformational and functional properties.
GNAI1 dysregulation is implicated in various diseases, including cancers, neurological disorders, and cardiovascular conditions. For instance, mutations or altered expression of GNAI1 have been linked to tumor progression and aberrant signaling in certain malignancies. Recombinant GNAI1 serves as a vital tool for dissecting these mechanisms, enabling drug discovery efforts targeting GPCR pathways. It is also used in biochemical assays (e.g., GTPase activity tests), structural studies (e.g., crystallography), and screening platforms to identify potential therapeutic modulators.
By providing a standardized, high-purity protein source, recombinant GNAI1 accelerates research into G protein signaling networks and their roles in health and disease, offering insights for developing targeted therapies.
×
